Return to content in this issue

 

Successful desensitization to alemtuzumab, with flow cytometric analysis of peripheral blood cells

Costa Carvalho J1, Macário MC2, Batista S2, Alen Coutinho I1, Laranjeira P3,4,5,6, Loureiro C1, Paiva A3,4,5,7, Todo Bom A1,8

1Allergy and Clinical Immunology Departement, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal.
2Neurology Departement, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal.
3Flow Citometry Unit, Clinical Pathology Departement, Centro Hospitalar e Universitário de Coimbra EPE, Coimbra, Portugal.
4Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
5Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal.
6Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.
7Instituto Politécnico de Coimbra, ESTESC-Coimbra Health School, Ciências Biomédicas Laboratoriais, Coimbra, Portugal.
8Institute of Pathophysiology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

J Investig Allergol Clin Immunol 2022; Vol. 32(6)
doi: 10.18176/jiaci.0795

Key words: Alemtuzumab, Desensitization, Flow Cytometry, Hypersensitivity, Multiple Sclerosis